

NAME and CONTACT DETAILS

Cédric Logé, Ph.D., Associate Professor (HDR) Phone: +33 (0)2 53 00 91 54
Nantes Université - IICIMED-UR1155 - Département de Chimie Thérapeutique
Institut de Recherche en Santé 2, 22 Boulevard Bénoni Goullin, 44200 Nantes, France
E-mail : cedric.loge@univ-nantes.fr



CAREER PROFILE

Education

Habilitation to Supervise Research (HDR) in Medicinal Chemistry, University of Nantes (2016)
PhD. in Medicinal Chemistry - Thesis: "Design and Synthesis of Rho-kinase inhibitors" (Adviser: Pr. Daniel Lesieur), University of Lille (2002)
MSc in Drug Design (Mastère), ICPAL, ENSCL, University of Lille (1999)
Master's degree (DEA) in Organic Chemistry, Pasteur Institute (Adviser: Pr. Christian Sergheraert) and University of Lille (1997)

Experience

2016-present: Senior Lecturer/Associate Professor of Medicinal Chemistry, University of Nantes.
2004-2016: Lecturer/Assistant Professor of Medicinal Chemistry, University of Nantes.
2003-2004: Research and Teaching Assistant (ATER), University of Nantes.
2002-2003: Postdoctoral Position in Molecular Modeling (Adviser: Pr. Philippe Chavatte), University of Lille.

Teaching Experience

Organic Chemistry (practical courses) and Medicinal Chemistry (antivirals, antimalarials, antifungals, kinase inhibitors) at the Faculty of Pharmacy (2nd to 5th year students). Molecular Modeling in Drug Design (Master's degree level).

RESEARCH

Valorization: 47 publications, 1 patent, 12 oral communications and invited lectures.

- **Scopus**  **Author ID:** 12783023500 **h-index:** 22
- **Orcid ID:**  <https://orcid.org/0000-0001-5113-6547>

Main areas of interest: In Silico Design (docking) and synthesis of new enzyme inhibitors in (1) oncology (protein kinase inhibitors) and (2) infectious diseases (fungal CYP51 inhibitors and parasitic protein kinase inhibitors).

Doctoral supervision: 5 PhD students (including one ongoing: Nov. 2023 - Dec. 2026), 13 Master's students.

Selected publications:

- P1.** Discovery of a novel broad-spectrum antifungal agent, derived from albaconazole. R. Guillon, F. Pagniez, C. Picot, D. Hedou, A. Tonnerre, E. Chosson, M. Duflos, T. Besson, **C. Logé**,* P. Le Pape. *ACS Medicinal Chemistry Letters*, **2013**, 4, 288-292.
https://doi.org/10.1021/ml300429p_ (Cited By in Scopus : 56) (IF 2012 = 3.311)
- P2.** New azole antifungals with a fused triazinone scaffold. **D. Montoir**, **R. Guillon**, S. Gazzola, I. Ourliac-Garnier, K. E. Soklou, A. Tonnerre, C. Picot, A. Planchat, F. Pagniez, P. Le Pape, **C. Logé**,* *European Journal of Medicinal Chemistry*, **2020**, 189, 112082.
<https://doi.org/10.1016/j.ejmech.2020.112082> (Cited By in Scopus : 25) (IF 2019 = 5.572)
- P3.** New quinoxaline derivatives as dual Pim-1/2 inhibitors: design, synthesis and biological evaluation. B. Oyallon, M. Brachet-Botineau, **C. Logé**, T. Robert, S. Bach, S. Ibrahim, W. Raoul, C. Croix, P. Berthelot, F. Gouilleux, M.-C. Viaud-Massuard, C. Denevault-Sabourin. *Molecules*, **2021**, 26, 867.
<https://doi.org/10.3390/molecules26040867> (Cited By in Scopus : 22) (IF 2020 = 4.411)
- P4.** Dibenzofuran derivatives inspired from cercosporamide as dual inhibitors of PIM and CLK1 kinases. V. H. Dao, I. Ourliac-Garnier, **C. Logé**, F. O. McCarthy, S. Bach, T. Gonçalves da Silva, C. Denevault-Sabourin, P. Le Pape, J. Thiéfaïne, B. Baratte, T. Robert, F. Gouilleux, M. Brachet-Botineau, M.-A. Bazin, P. Marchand. *Molecules*, **2021**, 26, 6572.
<https://doi.org/10.3390/molecules26216572> (Cited By in Scopus : 3) (IF 2020 = 4.411)
- P5.** Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy. L. Tisseur, **C. Logé**, S. Cojean, K. Gassama, L. Karcher, F. Pagniez, C. Cavé, G. Bernadat, P. M. Loiseau, S. Bach, J.

Thiéfaine, J. Bonnet, C. Picot, C. Tomasoni, O. Leclercq, B. Baratte, T. Robert, P. Le Pape, N. Rachidi, M.-A. Bazin, P. Marchand. *RSC Medicinal Chemistry*, **2025**, 16, 3746-3763.

<https://doi.org/10.1039/D5MD00257E>

(Cited By in Scopus : 0)

(IF 2024 = 4.1)

Patent awarded

Novel fused pyrimidinone and triazinone derivatives, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents. **C. Logé**, R. Guillon, D. Montoir, F. Pagniez, P. Le Pape. PCT WO **2017/020944** A1. Scientific lead of a project maturation with SATT Ouest Valorisation (Nov. **2014** – July **2018** / Project: DV2118-ANTIFONG / Funding: €140,000).

National Research Networks

ANR PRC OTARI (Organometallic-Containing Triazoles Against Resistant Fungi) - Oct. **2023** – March **2028** (54 months) - IICiMed-UR1155 / Chimie ParisTech, PSL University, CNRS

Project Coordinator: Dr. Kévin Cariou, CNRS Research Director – Partner 2 Scientific Lead: Cédric Logé, Associate professor, HDR) ANR Funding: €494,124 (Partner 2 funding: €186,707)

<https://anr.fr/Projet-ANR-23-CE18-0010>

ADMINISTRATIVE and EDUCATIONAL DUTIES

- Elected Head of the Educational Department E2M (Drug development, drug evaluation), faculty of pharmacy of Nantes (since **2025**).
- Elected Member of the Faculty Management Board (since **2021**).
- Member of the Faculty Research Committee (since **2024**).
- Elected Member of the Laboratory UR1155 Concil (since **2025**).
- Course Coordinator, Infectiology (UE8), 3rd Year Pharmacy Program (since **2018**).
- Co-creator and Coordinator of the optional “Drug Design” course, 3rd year pharmacy program (since **2022**).
- Course Coordinator, Industrial Project (UE IR11), 5th Year Pharmacy Program (since **2025**).
- Responsible for scheduling tutorials and practical sessions, 3rd Year Pharmacy Program – semester 2 (since **2023**).